VYND Vynleads Inc (QB)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

———————

FORM 10-Q

———————

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

  

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

Vynleads, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		333-227499		47-4584272
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation or Organization)		File Number)		Identification No.)

 

Address of Principal Executive Office: 596 Herrons Ferry Road, Suite 301, Rock Hill, SC 29730

 

Registrant’s telephone number, including area code: (845) 745-0981

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  þ  Yes  ¨ No

  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). þ Yes  ¨ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨	Accelerated filer   ¨
Non-accelerated filer     þ	Smaller reporting company  ☒
	Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes  þ No

 

As of May 14 2024, the registrant had 11,599,830 shares of common stock issued and outstanding.

 

 

 

DOCUMENTS INCORPORATED BY REFERENCE

None.

 

  

Vynleads, Inc.

 

 

 

FORM 10-Q

TABLE OF CONTENTS

 

		PAGE
	PART I
Item 1.	Financial Statements	2
	Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023	2
	Statements of Operations for the three months ended March 31, 2024 and 2023 (Unaudited)	3
	Statements of Stockholders’ Deficit for the three months ended March 31, 2024 and 2023 (Unaudited)	4
	Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (Unaudited)	5
	Notes to the Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20
	PART II
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	22

 

 

 

 

 

PART I

 

ITEM 1. FINANCIAL STATEMENTS.

 

Vynleads, Inc.

Balance Sheets

 

		March 31, 2024				December 31, 2023
			(Unaudited)
ASSETS
Current Assets:
Cash		$	2,737			$	14,513
Holdback receivable from merchant, net of reserve for refunds of $58 and $58, respectively			12,430				13,411
Prepaid expenses and other current assets			4,281				8,481
Total current assets			19,448				36,405
Total assets		$	19,448			$	36,405
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued expenses		$	289,181			$	277,524
Notes payable			507,309				487,807
Notes payable - related party			40,000				40,000
Total current liabilities			836,490				805,331
Total liabilities			836,490				805,331
Commitments and contingencies (See Note 6)			—				—
Stockholders' Deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding, respectively			—				—
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares issued and outstanding, respectively			1,160				1,160
Additional paid-in capital			1,786,752				1,754,252
Accumulated deficit			(2,604,954	)			(2,524,338	)
Total stockholders' deficit			(817,042	)			(768,926	)
Total liabilities and stockholders' deficit		$	19,448			$	36,405

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

Vynleads, Inc.

Statements of Operations

(Unaudited)

 

		For the three months ended
		March 31,
		2024				2023
Revenue, net of refunds and chargebacks		$	—			$	—
Cost and Expenses
Cost of revenue			4,235				12,922
Gross Loss			(4,235	)			(12,922	)
Operating Expenses
Selling, general and administrative expenses			69,755				56,836
Total Operating Expenses			69,755				56,836
Loss from operations			(73,990	)			(69,758	)
Other Expenses from operations
Interest expense			(6,626	)			(4,809	)
Net loss before provision for income taxes			(80,616	)			(74,567	)
Income Taxes			—				—
NET LOSS		$	(80,616	)		$	(74,567	)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC AND DILUTED		$	(0.01	)		$	(0.01	)
Weighted average common shares outstanding, basic and diluted			11,599,830				11,599,830

 

  

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

 

Vynleads, Inc.

Statements of Stockholders' Deficit

For the Three Months Ended March 31, 2024 and 2023

(Unaudited)

 

										Additional								Total
		Common Stock								Paid-In				Accumulated				Stockholders'
		Shares				Amount				Capital				Deficit				Deficit
Balance at December 31, 2022			11,599,830			$	1,160			$	1,624,252			$	(2,260,901	)		$	(635,489	)
In Kind Contribution of Services			—				—				32,500				—				32,500
Net Loss for the three months ended March 31, 2023			—				—				—				(74,567	)			(74,567	)
Balance at March 31, 2023 (Unaudited)			11,599,830				1,160				1,656,752				(2,335,468	)			(677,556	)
Balance at December 31, 2023			11,599,830			$	1,160			$	1,754,252			$	(2,524,338	)		$	(768,926	)
In Kind Contribution of Services			—				—				32,500				—				32,500
Net Loss for the three months ended March 31, 2024			—				—				—				(80,616	)			(80,616	)
Balance at March 31, 2024 (Unaudited)			11,599,830				1,160				1,786,752				(2,604,954	)			(817,042	)

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

 

Vynleads, Inc.

Statements of Cash Flows

(Unaudited)

 

		For the Three Months Ended
		March 31,
		2024				2023
Cash flows from operating activities:
Net loss		$	(80,616	)		$	(74,567	)
Adjustments to reconcile net loss to net cash flows used in operating activities
In kind contribution of services			32,500				32,500
Decrease in prepaid expenses and other current assets			5,181				3,990
(Decrease) increase in accounts payable and accrued expenses			11,159				(22,990	)
Net cash flows used in operating activities			(31,776	)			(61,067	)
Cash flows from financing activities:
Proceeds from notes payable			20,000				80,000
Proceeds from notes payable – related party			—				—
Net cash flows provided by financing activities			20,000				80,000
Net (decrease) increase in cash			(11,776	)			18,933
Cash at beginning of period			14,513				503
Cash at end of period		$	2,737			$	19,436
Supplemental disclosure of cash flow information:
Income taxes paid		$	—			$	—
Interest paid		$	—			$	—

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

VYNLEADS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

March 31, 2024

(UNAUDITED)

 

1.       Business

 

Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who are pre-diabetes or who have type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics.

Our corporate headquarters are located in Rock Hill, South Carolina.

2.       Going Concern

 

Our unaudited condensed financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt and equity securities, as well as borrowings from related parties. During the quarters ended March 31, 2024 and 2023, we have reported net losses of $80,616 and $74,567, respectively. As of March 31, 2024, we had a negative working capital of $817,042 and an accumulated deficit of $2,604,954. As a result, management believes that there is substantial doubt about our ability to continue as a going concern.

 

Despite our current expense, cash flow projections, and aggregate cash and holdback receivable from our merchant, net of reserve for refunds, of $12,430, we will require substantial funds to expand service and product offerings into additional areas, market and promote our services and product offerings; and develop and grow our infrastructure and corporate organization. Our capital requirements depend on numerous factors, including but not limited to our ability to generate sufficient revenues to pay our operating expenses.

 

Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome from this uncertainty.

 

3.       Summary of Significant Accounting Policies

 

Accounting Principles

 

The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

 

Use of Accounting Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgment is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.

 

 

6

 

 

Cash

 

Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.

 

Holdback Receivable

 

Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $58 and $58 as of March 31, 2024 and December 31, 2023, respectively.

 

Revenue Recognition

 

The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) and Accounting Standard Codification (ASC) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition.

 

We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue.

 

Our percentages of revenue by type for the three months ended March 31, 2024 and 2023 are as follows:

Schedule of percentage of revenue
		Three months ended
		March 31,
		(Unaudited)
		2024				2023
Internet content subscriptions			0.0	%			0.0	%
Nutritional supplements			0.0	%			0.0	%

 

Shipping and Handling Costs

 

We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.

 

 

7

 

Loss Per Share

 

Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 100,000 and 585,766 shares for the three months ended March 31, 2024 and 2023, respectively.

 

Income Taxes

 

The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.

 

We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.

 

Stock-Based Compensation

 

We account for stock based instruments issued to employees and non-employees for services in accordance with ASC Topic 718.

 

Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value.

 

The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value:

 

	·	the stock option exercise price;
	·	the expected term of the option;
	·	the grant date price of our common stock, which is issuable upon exercise of the option;
	·	the expected volatility of our common stock;
	·	the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and
	·	the risk-free interest rate for the expected option term.

 

Expected Dividends. We have never declared or paid any cash dividends on any of our capital stock and do not expect to do so in the foreseeable future. Accordingly, we use an expected dividend yield of zero to calculate the grant-date fair value of a stock option.

 

 

8

 

 

Expected Volatility. The expected volatility is a measure of the amount by which our stock price is expected to fluctuate during the expected term of options granted. We determine the expected volatility solely based upon the historical volatility of our common stock over a period commensurate with the option’s expected term. We do not believe that the future volatility of our common stock over an option’s expected term is likely to differ significantly from the past.

 

Risk-Free Interest Rate. The risk-free interest rate is the implied yield available on U.S. Treasury zero-coupon issues with a remaining term equal to the option’s expected term on the grant date.

 

Expected Term. For option grants subsequent to the adoption of the fair value recognition provisions of the accounting standards, the expected life of stock options granted is based on the actual vesting date and the end of the contractual term.

 

Grant Date Price of Common Stock. The closing market price of our common stock on the date of grant.

 

Fair Value of Financial Instruments

 

We follow ASC 820-10, “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:

 

Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price.

 

Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments.

 

Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity.

 

The carrying amounts of our cash, holdback receivable, prepaid expenses and other current assets, and accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of March 31, 2024 and December 31, 2023.

 

Recent Accounting Pronouncements

 

We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

 

 

9

 

4.       Related Party Transactions

 

On July 5, 2023, the company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or a date in the which the company secures one million in total investment capital, whichever occurs first. Accrued interest as of March 31, 2024 and December 31, 2023 is $969 and $657, respectively.

 

On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest as of March 31, 2024 and December 31, 2023 is $2,285 and $2,098 respectively. This note is currently in default.

 

On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share, which vested upon the effectiveness of the registration statement on December 7, 2018.

 

On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2024 and 2023, $32,500 and $32,500, respectively, is recorded as in-kind contribution of service provided by Mr. Mannine (See Notes 6 and 8).

 

On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2023.

 

As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including:

 

·

a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG;

 

·

a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG;

 

·

a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and

 

·

a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG.

 

In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

 

On January 23, 2024, Mr. Sergei Stetsenko sold 1,250,000 shares of common stock to Christos Livadas, Director of Weiser Global Capital, who is a current debt holder of notes payable. Effective January 23, 2024, notes payable associated to Christos Livadas, Weiser Global Capital, or WG Capital, are reflected as related party debt.

 

 

10

 

 

5.       Notes Payable

 

The following table summarizes notes payable as of March 31, 2024 and December 31, 2023:

Schedule of notes payable
Type		Original Amount	Origination Date	Maturity Date	Annual Interest Rate		Balance at March 31, 2024		Balance at December 31, 2023
Note Payable** (a)	$	50,000	11/18/2019	5/22/2020	5%	$	50,000	$	50,000
Note Payable** (b)	$	25,000	11/18/2019	5/22/2020	5%	$	25,000	$	25,000
Note Payable** (c)	$	27,000	05/20/2020	4/20/2022	1%	$	$8,307	$	8,307
Note Payable** (d)	$	10,000	10/27/2020	5/1/2021	5%	$	10,000	$	10,000
Note Payable** (e)	$	19,500	12/17/2020	6/21/2021	5%	$	19,500	$	19,500
Note Payable** (f)	$	10,000	4/15/2021	10/18/2021	5%	$	10,000	$	10,000
Note Payable** (g)	$	20,000	5/10/2021	11/12/2021	5%	$	20,000	$	20,000
Note Payable** (h)	$	15,000	8/4/2021	2/6/2022	5%	$	15,000	$	15,000
Note Payable** (i)	$	50,000	9/28/2021	4/2/2022	5%	$	50,000	$	50,000
Note Payable** (j)	$	15,000	12/1/2021	6/5/2022	5%	$	15,000	$	15,000
Note Payable** (k)	$	20,000	1/26/2022	7/31/2022	5%	$	20,000	$	20,000
Note Payable** (l)	$	20,000	2/10/2022	8/15/2022	5%	$	20,000	$	20,000
Note Payable** (m)	$	40,000	5/18/2022	11/20/2022	5%	$	40,000	$	40,000
Note Payable** (n)	$	20,000	8/12/2022	2/14/2023	5%	$	20,000	$	20,000
Note Payable** (o)	$	25,000	10/20/2022	4/24/2023	5%	$	25,000	$	25,000
Note Payable** (p)	$	20,000	1/12/2023	7/17/2023	5%	$	20,000	$	20,000
Note Payable** (q)	$	60,000	3/1/2023	9/3/2023	5%	$	60,000	$	60,000
Note Payable** (r)	$	10,000	5/17/2023	11/19/2023	5%	$	10,000	$	10,000
Note Payable (s)	$	20,000	10/25/2023	4/28/2024	5%	$	20,000	$	20,000
Note Payable (t)	$	15,000	11/22/2023	5/26/2024	5%	$	15,000	$	15,000
Note Payable (u)	$	15,000	12/27/2023	6/30/2024	5%	$	15,000	$	15,000
Note Payable (v)	$	20,000	2/14/2024	6/30/2024	5%	$	20,000	$	—
					Balance	$	507,807	$	487,807
					Less current portion	$	(507,807)	$	(487,807)
					Total long-term	$	—	$	—

** Currently in default

(a)

On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020 $1,250 of accrued interest was paid.

 

(b)

On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(c)

On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. We have used the entire loan amount for qualifying expenses and the forgiveness is pending the completion of the application. The Company received a $6,250 courtesy credit from the lender on September 15, 2021. As of March 31, 2024 and December 31, 2023 , the loan balance was $7,808 and 8,833, respectively. The monthly payment beginning October 4, 2021 is $3,433. The Company has submitted the application for forgiveness of the PPP Loan in accordance with the terms of the CARES Act and are in discussions with Bank of America (the lender). During the loan forgiveness process, repayment is temporarily deferred for borrowers until the SBA remits the final loan forgiveness amount to the lender. If granted full forgiveness, Bank of America confirmed that interest and penalties would be removed along with the principal of the loan.

 

(d)

On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

 

11

 

(e)

On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(f)

On April 15, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

(g)

On May 10, 2021, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(h)

On August 4, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(i)

On September 28, 2021, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

(j)

On December 1, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(k)

On January 26, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(l)

On February 10, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

(m)

On May 18, 2022, the Company executed a note payable to an individual in the amount of $40,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(n)

On August 12, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

(o)

On October 20, 2022, the Company executed a note payable to an individual in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first

 

(p)

On January 12, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

(q)

On March 2, 2023, the Company executed a note payable to an individual in the amount of $60,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

(r)

On May 19, 2023, the Company executed a note payable to an individual in the amount of $10,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

12

(s)

On October 25, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

(t)

On November 22, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

(u)

On December 27, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

(v)

On February 14, 2024, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

The following table summarizes notes payable, related parties as of March 31, 2024 and December 31, 2023:

Schedule of related parties notes payable
Type		Original Amount	Origination Date	Maturity Date	Annual Interest Rate		Balance at March 31, 2024		Balance at December 31, 2023
Note Payable (RP)** (w)	$	15,000	3/16/2021	9/18/2021	5%	$	15,000	$	15,000
Note Payable (RP)** (x)	$	25,000	6/23/2023	12/26/2023	5%	$	25,000	$	—
					Balance	$	40,000	$	15,000
					Less current portion	$	(40,000)	$	(15,000)
					Total long-term	$	—	$	—

** Currently in default

(w)

On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

 

(x)

On July 5, 2022, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

 

The Company had total accrued interest for related party and non-related party notes payable of $56,442 and $50,364, as of March 31, 2024 and December 31, 2023, respectively.

 

13

  

6.       Commitments and Contingencies

 

Employment Agreement

 

On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term.

 

Mr. Mannine’s compensation includes:

 

	·	an annual base salary of $130,000, subject to an annual review with an increase of at least 5% per annum as determined by the board of directors;
	·	an annual bonus as determined by the board of directors;
	·	a grant of 10-year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share which vest upon the effectiveness of a registration statement to be filed with the Securities and Exchange Commission;
	·	participation in all benefit plans we may offer our employees; and
	·	20 paid vacation days annually.

 

 

14

 

Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows:

 

	·	if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation);
	·	if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or
	·	if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid.

 

The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses.

 

On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2024 and 2023, $32,500 and $32,500, respectively, is recorded as in-kind contribution of service provided by Mr. Mannine (See Notes 4 and 8).

 

Commitments

  

On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2024.

 

As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including:

 

	·	a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG;
	·	a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG;
	·	a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and
	·	a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG.

 

 

 

15

 

In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

  

Contingencies

 

In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non-payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

 

7.       Concentration of Credit Risk and Major Customers and Suppliers

 

We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

 

8.       Stockholders’ Deficit

 

Our authorized capital stock consists of 50,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of blank check preferred stock, par value $0.0001 per share. As of March 31, 2024 and December 31, 2023, there are 11,599,830 and 11,599,830 shares of common stock outstanding and there are no shares of preferred stock issued and outstanding at either date.

 

Contributed Capital

On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. The salary forgiven for the three months ended March 31, 2024 and 2023 of $32,500 and $32,500 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See notes 4 and 8).

Preferred Stock

Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding.

Warrants

On October 10, 2017, we entered into the Financing Agreement with CRG, as more fully described in Notes 4 and 8. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 fully vested five-year warrants with an exercise price of $0.225. The related warrants were issued in January 2018. We determined that the warrant had an initial fair value of $34,405 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 5 years. The warrants expired as of March 31, 2023.

 

During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 fully vested common stock warrants with an exercise price of $0.225. These additional warrants were issued to CRG on January 30, 2018. We determined that the warrant had an initial fair value of $1,670 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.51% and an expected life of 5 years. The warrants expired as of March 31, 2023.

 

On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 five-year common stock warrants at an exercise price of $0.90. Such warrants vest subject to certain milestones. As of March 31, 2024 and December 31 2023, 0 and 0 of these warrants have been vested. We determined that the warrant had an initial fair value of $1,905. We estimated the fair value of this warrant using the Black- Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.63% and an expected life of 5 years. The warrants expired as of March 31, 2023.

 

As of March 31, 2024 and December 31, 2023, the intrinsic value for warrants outstanding and exercisable is $0 and $0, respectively.

 

The following table summarizes information about the warrants outstanding and exercisable as of March 31, 2024 and December 31 2023:

 

Schedule of warrants outstanding and exercisable
		2024								2023
		Warrants				Weighted Average Exercise Price				Warrants				Weighted Average Exercise Price
Outstanding, beginning of year			—			$	—				485,766			$	0.364
Granted			—				—				—				—
Exercised			—				—				—				—
Forfeited			—				—				—				—
Expired			—				—				485,766				—
Outstanding, end of year			—			$	—				—			$	—
Exercisable, end of year			—			$	—				—			$	—

 

As of March 31,2024, there were no outstanding common stock warrants.

 

16

 

 

9.       Stock Option Plan

 

In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 shares of our common stock for issuance under the 2017 Plan. Grants pursuant to the 2017 Plan may be: i) incentive stock options; ii) non-statutory stock options; iii) stock awards, including shares of our common stock and stock units; and iv) stock appreciation rights.

 

The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000.

 

Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferable.

 

Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately canceled .

 

In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant.

 

The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events.

 

On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 8, we issued 100,000 stock options with an exercise price of $0.225. Such options fully vest upon the effectiveness of a registration statement on Form S-1. We determined that the options had an initial fair value of $13,221. We estimated the fair value of these options using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 10 years. We amortized the fair value over the period from their issuance on June 14, 2018 through December 7, 2018, the date on which the registration statement was declared effective.

 

As of March 31, 2024 and December 31, 2023, the intrinsic value for option outstanding and exercisable is $0 and $0, respectively.

 

17

The following table summarizes information about stock options outstanding and exercisable as of as of March 31, 2024 and December 31, 2023 :

Schedule of information about stock options outstanding and exercisable
		March 31, 2024 (Unaudited)								December 31, 2023
							Weighted								Weighted
							Average								Average
							Exercise								Exercise
			Options				Price				Options				Price
Outstanding, beginning of period			100,000			$	0.225				100,000			$	0.225
Granted			—				—				—				—
Exercised			—				—				—				—
Forfeited			—				—				—				—
Expired			—				—				—				—
Outstanding, end of period			100,000			$	0.225				100,000			$	0.225
Exercisable, end of period			100,000			$	0.225				100,000			$	0.225
Options available for future grant, end of period			1,000,000								1,000,000

 

As of March 31, 2024

Schedule of options outstanding by exercisable price range
				Options Outstanding										Options Exercisable
Range of Exercise Price				Number Outstanding		Remaining Average Contractual Life (In Years)				Weighted Average Exercise Price				Number Exercisable		Weighted Average Exercise Price
$	0.225			100,000			4.21			$	0.225			100,000		$	0.225

As of December 31, 2023

				Options Outstanding									Options Exercisable
	Range of Exercise Price			Number Outstanding			Remaining Average Contractual Life (In Years)			Weighted Average Exercise Price			Number Exercisable		Weighted Average Exercise Price
$	0.225			100,000			4.46		$	0.225			100,000	$	0.225

 

10. Subsequent Events

 

On April 14, 2024, the company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or a date in the which the company secures one million in total investment capital, whichever occurs first.

 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Our financial statements are stated in United States Dollars and are prepared in accordance with the United States Generally Accepted Accounting Principles.

 

Results of Operations

 

The Company has incurred losses since inception resulting in an accumulated deficit of $2,604,954 as of March 31,2024. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

 

We will require additional capital to meet our short- and long-term operating requirements. We expect to raise additional capital through, among other things, the sale of equity securities.

 

Three months ended March 31, 2024 (“2024 first quarter”) compared to the three months ended March 31, 2023 (“2023 first quarter”)

 

Revenues

 

Revenues for the three months ended March 31, 2024 and March 31, 2023 was $0.

 

Costs and Expenses

 

Total costs and operating expenses decreased by $8,687 or 67% in the three months ended March 31, 2024 compared to the three months ended March 31, 2023. The decrease in operating cost and expense was due to savings initiative to offset the decline in revenue. Our cost of revenue includes the cost of the customer management system and merchant fees.

 

Selling, general and administrative expenses increased by $12,919 or 23% in the three months ended March 31, 2024 compared to the three months ended March 31, 2023. The increase in selling, general and administration expenses is principally attributable to increases in consulting and accounting expenses, legal expenses, office expenses and general expenses.

 

Net Loss

 

Our net loss for the three months ended March 31, 2024 was $80,616 compared to 74,567 for the three months ended March 31, 2023. Our net loss. Increase in net loss are attributable to the increase in selling, general and administrative costs.

 

 

 

 

Liquidity and capital resources

 

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs for cash. The following table summarizes our total current assets, total current liabilities and working capital deficit at March 31, 2024 as compared to December 31, 2023.

 

		March 31,				December 31,
		2024				2022
			(unaudited)
Total current assets		$	19,448			$	36,405
Total current liabilities		$	836,490			$	805,331
Working capital deficit		$	(817,042	)		$	(768,926	)

 

The reduction in total current assets between the periods primarily reflects a reduction in cash and decrease in prepaid expenses. The increase in total current liabilities reflects an increase in notes payable. We do not have any capital commitments and do not have any external sources of working capital available.

 

Going concern and management’s liquidity plans

  

We have experienced recurring operating losses and negative operating cash flows and have financed our recent working capital requirements primarily through the issuance of equity securities. During the three months ended March 31, 2024 and 2023, we have reported net losses of $80,616 and $74,567 respectively. As of March 31, 2024, we had a working capital deficit of $817,042, our accumulated deficit was $2,604,954. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our unaudited Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. The accompanying Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. There are no assurances we will be successful in our efforts to report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.

 

Our ability to continue to grow our business is dependent upon our ability to raise additional sufficient capital to fund our operating expenses, including advertising, until such time, if ever, that we are able to report profitable operations, as well as for our short-term and long-term growth plans. We do not generate operating income and we are presently are relying on cash we receive from the holdback receivable to pay our operating expenses. Our management estimates that we require approximately $5,500,000 in additional working capital during the next 12 months in order to meet our current business objectives, including the development of new indicators for our Lifestyle Blueprint platform, the addition of print versions of our DWD Protocol, expanding our supplement product line and additional subscription content offerings for our customers. This additional working capital is also necessary to fund increases in our advertising and marketing costs, costs associated with the development of additional infrastructure to support our expected growth, as well as funds to pay our operating expenses and general working capital. While we were successful in raising funds privately during late 2017 and into the first quarter of 2018, and will seek to do so in future periods, we do not have any firm commitments to provide any additional capital to us. There are no assurances we will be successful in securing the additional capital necessary to grow our company and pay our operating expenses. Any delay in raising sufficient funds could adversely impact our ability to continue to increase our revenues in future periods. In addition, if we are unable to raise the necessary additional working capital, we may be forced to reduce certain operating expenses in an effort to conserve our working capital which will adversely impact our revenues and results of operations in future periods and there are no assurances we could continue as a going concern.

 

 

 

 

Summary of cash flows

 

		March 31,				March 31,
		2024				2023
			(unaudited)				(unaudited)
Net cash used in operating activities		$	(31,776	)		$	(61,067	)
Net cash provided by investing activities		$	—			$	—
Net cash provided by financing activities		$	20,000			$	80,000

 

There was no net cash provided by or used in investing activities during the three months ended March 31, 2024 and 2023.

 

Net cash provided by financing activities during the three months ended March 31, 2024 decreased reflects a decrease in proceeds from notes payable.

 

Commitments and Contingencies

 

Information regarding our Commitments and Contingencies is contained in Note 6 to the unaudited Condensed Financial Statements.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Emerging Growth Company

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the “JOBS Act”, and we are permitted to take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal controls over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or the “Sarbanes-Oxley Act”, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an “emerging growth company.” In addition, the JOBS Act provides that an “emerging growth company” can delay adopting new or revised accounting standards until such time as

those standards apply to private companies.

 

We have elected to use the extended transition period for complying with new or revised accounting standards under the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

 

We could remain an emerging growth company for up to five years, or until the earliest of:

 

	·	the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion;
	·	the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the “Exchange Act”, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or
	·	the date we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

 

At this time, we expect to remain an emerging growth company until possibly as late as 2023. References herein to “emerging growth company” have the meaning associated with that term in the JOBS Act.

 

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable to smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management has concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Report to provide the reasonable assurance discussed above.

 

Management's Annual Report on Internal Control Over Financial Reporting

 

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Securities Exchange Act Rule 13a-15(f). The Company carried out an evaluation under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s internal control over financial reporting. The Company’s management used the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations (COSO) to perform this evaluation. As a result of this assessment, management identified a material weakness in internal control over financial reporting. A material weakness is a control deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The identified material weakness is disclosed below:

 

·

Due to the size of the Company and available resources, there are limited personnel to assist with the accounting and financial reporting function, which results in a lack of segregation of duties.

 

As a result of the material weakness in internal control over financial reporting described above, management concluded that, as of March 31, 2024, the Company’s internal control over financial reporting was not effective based on the criteria in Internal Control – Integrated Framework issued by the COSO. Management notes that upon subsequent funding, the Company expects to have the available resources in order to hire additional personnel to expand the finance and accounting department in order to mitigate the material weakness noted above.

 

This quarterly report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we, engaged our independent registered public accounting firm to perform an audit of internal control over financial reporting pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report. 

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

   

 

PART II – OTHER INFORMATION

  

ITEM 1. LEGAL PROCEEDINGS

 

In 2016 we engaged a third party to provide certain promotional services to us in connection with our business, including the use of his name and appearance, under the terms of a five-year agreement. As compensation, we agreed to use our commercially reasonable efforts to promote and sell a book authored by him and to pay him, as a royalty, a percentage of the sales of the book, after deductions for all direct costs of fulfilling such sales. During 2017 the third party initiated a series of informal claims and filed unauthorized uniform commercial code (UCC) financing statements in several states against us and certain of our officers, directors, and founders, alleging non-payment of the royalty amounts. We dispute all claims by the third party and believe that all royalty amounts due him have been paid in full. We are no longer selling the book authored by him. We have succeeded in removing certain of the UCC liens and we are pursuing actions to remove the remaining unauthorized UCC lien.

 

ITEM 1A. RISK FACTORS

 

Not applicable to smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

On October 25, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. This note is currently in default.

On October 20, 2022, the Company executed a note payable to an individual in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or the date in the which the company secures one million in total investment capital, whichever occurs first.

 

On August 12, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or the date in the which the company secures one million in total investment capital, whichever occurs first.

 

On May 18, 2022, the Company executed a note payable to an individual in the amount of $40,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the company secures one million dollars in total investment capital, whichever occurs first.

On February 10, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

On January 26, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

On December 1, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

On September 28, 2021, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

 

 

On August 4, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

On May 10, 2021, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

On April 15, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. The note is currently in default.

 

On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020 $1,250 of accrued interest was paid. This note is currently in default.

 

On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. This note is currently in default.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K. 

 

ITEM 6. EXHIBITS

 

The following exhibits are filed as part of this Quarterly Report on Form 10-Q:

 

Exhibit				Incorporated by Reference						Filed or Furnished
No.		Exhibit Description		Form		Date Filed		Number		Herewith
31.1		Certification of Chief Executive Officer, principal executive officer, principal financial and accounting officer								Filed
32.1		Certification of Chief Executive Officer, principal executive officer, principal financial and accounting officer								Filed

 

 

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	By:	/s/ Alex J. Mannine
		Alex J. Mannine Chief Executive Officer, director, principal executive officer, principal financial and accounting officer May 14, 2024

 

 

 

 

 

 

 

EXHIBIT 31.1

CERTIFICATION

I, Alex J. Mannine, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Vynleads, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 14, 2024	By:	/s/ Alex J. Mannine
		Alex J. Mannine, Chief Executive Officer, principal executive officer, principal financial and accounting officer

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report on Form 10-Q of Vynleads, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alex J. Mannine, Chief Executive Officer and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that,

 

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.	To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 14, 2024	By:	/s/ Alex J. Mannine
		Alex J. Mannine, Chief Executive Officer, principal executive officer, principal financial and accounting officer

v3.24.1.1.u2

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	333-227499
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Entity Tax Identification Number	47-4584272
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	596 Herrons Ferry Road
Entity Address, Address Line Two	Suite 301
Entity Address, City or Town	Rock Hill
Entity Address, State or Province	SC
Entity Address, Postal Zip Code	29730
City Area Code	845
Local Phone Number	745-0981
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,599,830

v3.24.1.1.u2

Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 2,737	$ 14,513
Holdback receivable from merchant, net of reserve for refunds of $58 and $58, respectively	12,430	13,411
Prepaid expenses and other current assets	4,281	8,481
Total current assets	19,448	36,405
Total assets	19,448	36,405
Current Liabilities:
Accounts payable and accrued expenses	289,181	277,524
Notes payable	507,309	487,807
Notes payable - related party	40,000	40,000
Total current liabilities	836,490	805,331
Total liabilities	836,490	805,331
Commitments and contingencies (See Note 6)
Stockholders' Deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares issued and outstanding, respectively	1,160	1,160
Additional paid-in capital	1,786,752	1,754,252
Accumulated deficit	(2,604,954)	(2,524,338)
Total stockholders' deficit	(817,042)	(768,926)
Total liabilities and stockholders' deficit	$ 19,448	$ 36,405

v3.24.1.1.u2

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Net of reserve for refunds	$ 58	$ 58
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,599,830
Common stock, shares outstanding	11,599,830	11,599,830

v3.24.1.1.u2

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue, net of refunds and chargebacks	$ 0	$ 0
Cost and Expenses
Cost of revenue	4,235	12,922
Gross Loss	(4,235)	(12,922)
Operating Expenses
Selling, general and administrative expenses	69,755	56,836
Total Operating Expenses	69,755	56,836
Loss from operations	(73,990)	(69,758)
Other Expenses from operations
Interest expense	(6,626)	(4,809)
Net loss before provision for income taxes	(80,616)	(74,567)
Income Taxes	0	0
NET LOSS	$ (80,616)	$ (74,567)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC	$ (0.01)	$ (0.01)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS: DILUTED	$ (0.01)	$ (0.01)
Weighted average common shares outstanding, basic	11,599,830	11,599,830
Weighted average common shares outstanding, diluted	11,599,830	11,599,830

v3.24.1.1.u2

Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022	$ 1,160	$ 1,624,252	$ (2,260,901)	$ (635,489)
Beginning balance, shares at Dec. 31, 2022	11,599,830
In Kind Contribution of Services		32,500		32,500
Net Loss			(74,567)	(74,567)
Ending balance, value at Mar. 31, 2023	$ 1,160	1,656,752	(2,335,468)	(677,556)
Ending balance, shares at Mar. 31, 2023	11,599,830
Beginning balance, value at Dec. 31, 2023	$ 1,160	1,754,252	(2,524,338)	(768,926)
Beginning balance, shares at Dec. 31, 2023	11,599,830
In Kind Contribution of Services		32,500		32,500
Net Loss			(80,616)	(80,616)
Ending balance, value at Mar. 31, 2024	$ 1,160	$ 1,786,752	$ (2,604,954)	$ (817,042)
Ending balance, shares at Mar. 31, 2024	11,599,830

v3.24.1.1.u2

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (80,616)	$ (74,567)
Adjustments to reconcile net loss to net cash flows used in operating activities
In kind contribution of services	32,500	32,500
Decrease in prepaid expenses and other current assets	5,181	3,990
(Decrease) increase in accounts payable and accrued expenses	11,159	(22,990)
Net cash flows used in operating activities	(31,776)	(61,067)
Cash flows from financing activities:
Proceeds from notes payable	20,000	80,000
Proceeds from notes payable – related party	0	0
Net cash flows provided by financing activities	20,000	80,000
Net (decrease) increase in cash	(11,776)	18,933
Cash at beginning of period	14,513	503
Cash at end of period	2,737	19,436
Supplemental disclosure of cash flow information:
Income taxes paid	0	0
Interest paid	$ 0	$ 0

v3.24.1.1.u2

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (80,616)	$ (74,567)

v3.24.1.1.u2

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

v3.24.1.1.u2

Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1.       Business   Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who are pre-diabetes or who have type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

v3.24.1.1.u2

Going Concern	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2.       Going Concern   Our unaudited condensed financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt and equity securities, as well as borrowings from related parties. During the quarters ended March 31, 2024 and 2023, we have reported net losses of $80,616 and $74,567, respectively. As of March 31, 2024, we had a negative working capital of $817,042 and an accumulated deficit of $2,604,954. As a result, management believes that there is substantial doubt about our ability to continue as a going concern.   Despite our current expense, cash flow projections, and aggregate cash and holdback receivable from our merchant, net of reserve for refunds, of $12,430, we will require substantial funds to expand service and product offerings into additional areas, market and promote our services and product offerings; and develop and grow our infrastructure and corporate organization. Our capital requirements depend on numerous factors, including but not limited to our ability to generate sufficient revenues to pay our operating expenses.   Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome from this uncertainty.

v3.24.1.1.u2

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3.       Summary of Significant Accounting Policies   Accounting Principles   The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).   Use of Accounting Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgment is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.   Cash   Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.   Holdback Receivable   Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $58 and $58 as of March 31, 2024 and December 31, 2023, respectively.   Revenue Recognition   The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) and Accounting Standard Codification (ASC) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition.   We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue.   Our percentages of revenue by type for the three months ended March 31, 2024 and 2023 are as follows: Schedule of percentage of revenue                 Three months ended       March 31,       (Unaudited)       2024     2023   Internet content subscriptions     0.0 %     0.0 % Nutritional supplements     0.0 %     0.0 %   Shipping and Handling Costs   We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.   Loss Per Share   Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 100,000 and 585,766 shares for the three months ended March 31, 2024 and 2023, respectively.   Income Taxes   The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases.   Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.   We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.   Stock-Based Compensation   We account for stock based instruments issued to employees and non-employees for services in accordance with ASC Topic 718.   Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value.   The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value:     · the stock option exercise price;   · the expected term of the option;   · the grant date price of our common stock, which is issuable upon exercise of the option;   · the expected volatility of our common stock;   · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and   · the risk-free interest rate for the expected option term.   Expected Dividends. We have never declared or paid any cash dividends on any of our capital stock and do not expect to do so in the foreseeable future. Accordingly, we use an expected dividend yield of zero to calculate the grant-date fair value of a stock option.   Expected Volatility. The expected volatility is a measure of the amount by which our stock price is expected to fluctuate during the expected term of options granted. We determine the expected volatility solely based upon the historical volatility of our common stock over a period commensurate with the option’s expected term. We do not believe that the future volatility of our common stock over an option’s expected term is likely to differ significantly from the past.   Risk-Free Interest Rate. The risk-free interest rate is the implied yield available on U.S. Treasury zero-coupon issues with a remaining term equal to the option’s expected term on the grant date.   Expected Term. For option grants subsequent to the adoption of the fair value recognition provisions of the accounting standards, the expected life of stock options granted is based on the actual vesting date and the end of the contractual term.   Grant Date Price of Common Stock. The closing market price of our common stock on the date of grant.   Fair Value of Financial Instruments   We follow ASC 820-10, “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.   The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:   Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price.   Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments.   Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity.   The carrying amounts of our cash, holdback receivable, prepaid expenses and other current assets, and accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of March 31, 2024 and December 31, 2023.   Recent Accounting Pronouncements   We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

v3.24.1.1.u2

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	4.       Related Party Transactions   On July 5, 2023, the company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or a date in the which the company secures one million in total investment capital, whichever occurs first. Accrued interest as of March 31, 2024 and December 31, 2023 is $969 and $657, respectively.   On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest as of March 31, 2024 and December 31, 2023 is $2,285 and $2,098 respectively. This note is currently in default.   On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share, which vested upon the effectiveness of the registration statement on December 7, 2018.   On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2024 and 2023, $32,500 and $32,500, respectively, is recorded as in-kind contribution of service provided by Mr. Mannine (See Notes 6 and 8).   On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2023.   As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including:     · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG;     · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG;     · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and     · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG.   In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.   On January 23, 2024, Mr. Sergei Stetsenko sold 1,250,000 shares of common stock to Christos Livadas, Director of Weiser Global Capital, who is a current debt holder of notes payable. Effective January 23, 2024, notes payable associated to Christos Livadas, Weiser Global Capital, or WG Capital, are reflected as related party debt.

v3.24.1.1.u2

Notes Payable	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	5.       Notes Payable   The following table summarizes notes payable as of March 31, 2024 and December 31, 2023: Schedule of notes payable                   Type   Original Amount Origination Date Maturity Date Annual Interest Rate   Balance at March 31, 2024   Balance at December 31, 2023 Note Payable** (a) $ 50,000 11/18/2019 5/22/2020 5% $ 50,000 $ 50,000 Note Payable** (b) $ 25,000 11/18/2019 5/22/2020 5% $ 25,000 $ 25,000 Note Payable** (c) $ 27,000 05/20/2020 4/20/2022 1% $ $8,307 $ 8,307 Note Payable** (d) $ 10,000 10/27/2020 5/1/2021 5% $ 10,000 $ 10,000 Note Payable** (e) $ 19,500 12/17/2020 6/21/2021 5% $ 19,500 $ 19,500 Note Payable** (f) $ 10,000 4/15/2021 10/18/2021 5% $ 10,000 $ 10,000 Note Payable** (g) $ 20,000 5/10/2021 11/12/2021 5% $ 20,000 $ 20,000 Note Payable** (h) $ 15,000 8/4/2021 2/6/2022 5% $ 15,000 $ 15,000 Note Payable** (i) $ 50,000 9/28/2021 4/2/2022 5% $ 50,000 $ 50,000 Note Payable** (j) $ 15,000 12/1/2021 6/5/2022 5% $ 15,000 $ 15,000 Note Payable** (k) $ 20,000 1/26/2022 7/31/2022 5% $ 20,000 $ 20,000 Note Payable** (l) $ 20,000 2/10/2022 8/15/2022 5% $ 20,000 $ 20,000 Note Payable** (m) $ 40,000 5/18/2022 11/20/2022 5% $ 40,000 $ 40,000 Note Payable** (n) $ 20,000 8/12/2022 2/14/2023 5% $ 20,000 $ 20,000 Note Payable** (o) $ 25,000 10/20/2022 4/24/2023 5% $ 25,000 $ 25,000 Note Payable** (p) $ 20,000 1/12/2023 7/17/2023 5% $ 20,000 $ 20,000 Note Payable** (q) $ 60,000 3/1/2023 9/3/2023 5% $ 60,000 $ 60,000 Note Payable** (r) $ 10,000 5/17/2023 11/19/2023 5% $ 10,000 $ 10,000 Note Payable (s) $ 20,000 10/25/2023 4/28/2024 5% $ 20,000 $ 20,000 Note Payable (t) $ 15,000 11/22/2023 5/26/2024 5% $ 15,000 $ 15,000 Note Payable (u) $ 15,000 12/27/2023 6/30/2024 5% $ 15,000 $ 15,000 Note Payable (v) $ 20,000 2/14/2024 6/30/2024 5% $ 20,000 $ —                               Balance $ 507,807 $ 487,807           Less current portion $ (507,807) $ (487,807)           Total long-term $ — $ — ** Currently in default (a) On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020 $1,250 of accrued interest was paid.   (b) On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (c) On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. We have used the entire loan amount for qualifying expenses and the forgiveness is pending the completion of the application. The Company received a $6,250 courtesy credit from the lender on September 15, 2021. As of March 31, 2024 and December 31, 2023 , the loan balance was $7,808 and 8,833, respectively. The monthly payment beginning October 4, 2021 is $3,433. The Company has submitted the application for forgiveness of the PPP Loan in accordance with the terms of the CARES Act and are in discussions with Bank of America (the lender). During the loan forgiveness process, repayment is temporarily deferred for borrowers until the SBA remits the final loan forgiveness amount to the lender. If granted full forgiveness, Bank of America confirmed that interest and penalties would be removed along with the principal of the loan.   (d) On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (e) On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (f) On April 15, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (g) On May 10, 2021, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (h) On August 4, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (i) On September 28, 2021, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (j) On December 1, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (k) On January 26, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (l) On February 10, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (m) On May 18, 2022, the Company executed a note payable to an individual in the amount of $40,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (n) On August 12, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. (o) On October 20, 2022, the Company executed a note payable to an individual in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first   (p) On January 12, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (q) On March 2, 2023, the Company executed a note payable to an individual in the amount of $60,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (r) On May 19, 2023, the Company executed a note payable to an individual in the amount of $10,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. (s) On October 25, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (t) On November 22, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (u) On December 27, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (v) On February 14, 2024, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   The following table summarizes notes payable, related parties as of March 31, 2024 and December 31, 2023: Schedule of related parties notes payable                   Type   Original Amount Origination Date Maturity Date Annual Interest Rate   Balance at March 31, 2024   Balance at December 31, 2023 Note Payable (RP)** (w) $ 15,000 3/16/2021 9/18/2021 5% $ 15,000 $ 15,000 Note Payable (RP)** (x) $ 25,000 6/23/2023 12/26/2023 5% $ 25,000 $ —                               Balance $ 40,000 $ 15,000           Less current portion $ (40,000) $ (15,000)           Total long-term $ — $ — ** Currently in default (w) On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (x) On July 5, 2022, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   The Company had total accrued interest for related party and non-related party notes payable of $56,442 and $50,364, as of March 31, 2024 and December 31, 2023, respectively.

v3.24.1.1.u2

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6.       Commitments and Contingencies   Employment Agreement   On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term.   Mr. Mannine’s compensation includes:     · an annual base salary of $130,000, subject to an annual review with an increase of at least 5% per annum as determined by the board of directors;   · an annual bonus as determined by the board of directors;   · a grant of 10-year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share which vest upon the effectiveness of a registration statement to be filed with the Securities and Exchange Commission;   · participation in all benefit plans we may offer our employees; and   · 20 paid vacation days annually.   Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows:     · if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation);   · if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or   · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid.   The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses.   On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2024 and 2023, $32,500 and $32,500, respectively, is recorded as in-kind contribution of service provided by Mr. Mannine (See Notes 4 and 8).   Commitments    On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2024.   As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including:     · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG;   · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG;   · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and   · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG.   In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.    Contingencies   In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non-payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

v3.24.1.1.u2

Concentration of Credit Risk and Major Customers and Suppliers	3 Months Ended
	Mar. 31, 2024
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	7.       Concentration of Credit Risk and Major Customers and Suppliers   We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

v3.24.1.1.u2

Stockholders’ Deficit	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Deficit	8.       Stockholders’ Deficit   Our authorized capital stock consists of 50,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of blank check preferred stock, par value $0.0001 per share. As of March 31, 2024 and December 31, 2023, there are 11,599,830 and 11,599,830 shares of common stock outstanding and there are no shares of preferred stock issued and outstanding at either date.   Contributed Capital On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. The salary forgiven for the three months ended March 31, 2024 and 2023 of $32,500 and $32,500 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See notes 4 and 8). Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants On October 10, 2017, we entered into the Financing Agreement with CRG, as more fully described in Notes 4 and 8. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 fully vested five-year warrants with an exercise price of $0.225. The related warrants were issued in January 2018. We determined that the warrant had an initial fair value of $34,405 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 5 years. The warrants expired as of March 31, 2023.   During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 fully vested common stock warrants with an exercise price of $0.225. These additional warrants were issued to CRG on January 30, 2018. We determined that the warrant had an initial fair value of $1,670 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.51% and an expected life of 5 years. The warrants expired as of March 31, 2023.   On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 five-year common stock warrants at an exercise price of $0.90. Such warrants vest subject to certain milestones. As of March 31, 2024 and December 31 2023, 0 and 0 of these warrants have been vested. We determined that the warrant had an initial fair value of $1,905. We estimated the fair value of this warrant using the Black- Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.63% and an expected life of 5 years. The warrants expired as of March 31, 2023.   As of March 31, 2024 and December 31, 2023, the intrinsic value for warrants outstanding and exercisable is $0 and $0, respectively.   The following table summarizes information about the warrants outstanding and exercisable as of March 31, 2024 and December 31 2023:   Schedule of warrants outstanding and exercisable                                     2024     2023       Warrants     Weighted Average Exercise Price     Warrants     Weighted Average Exercise Price   Outstanding, beginning of year     —       $ —         485,766     $ 0.364   Granted     —         —         —         —     Exercised     —         —         —         —     Forfeited     —         —         —         —     Expired     —         —         485,766       —     Outstanding, end of year     —       $ —         —       $ —     Exercisable, end of year     —       $ —         —       $ —       As of March 31,2024, there were no outstanding common stock warrants.

v3.24.1.1.u2

Stock Option Plan	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Option Plan	9.       Stock Option Plan   In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 shares of our common stock for issuance under the 2017 Plan. Grants pursuant to the 2017 Plan may be: i) incentive stock options; ii) non-statutory stock options; iii) stock awards, including shares of our common stock and stock units; and iv) stock appreciation rights.   The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000.   Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferable.   Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately canceled .   In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant.   The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events.   On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 8, we issued 100,000 stock options with an exercise price of $0.225. Such options fully vest upon the effectiveness of a registration statement on Form S-1. We determined that the options had an initial fair value of $13,221. We estimated the fair value of these options using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 10 years. We amortized the fair value over the period from their issuance on June 14, 2018 through December 7, 2018, the date on which the registration statement was declared effective.   As of March 31, 2024 and December 31, 2023, the intrinsic value for option outstanding and exercisable is $0 and $0, respectively. The following table summarizes information about stock options outstanding and exercisable as of as of March 31, 2024 and December 31, 2023 : Schedule of information about stock options outstanding and exercisable                             March 31, 2024 (Unaudited)     December 31, 2023                                           Weighted               Weighted                 Average               Average                 Exercise               Exercise         Options       Price       Options       Price   Outstanding, beginning of period     100,000     $ 0.225       100,000     $ 0.225        Granted     —         —         —         —          Exercised     —         —         —         —          Forfeited     —         —         —         —          Expired     —         —         —         —     Outstanding, end of period     100,000     $ 0.225       100,000     $ 0.225   Exercisable, end of period     100,000     $ 0.225       100,000     $ 0.225                                     Options available for future grant, end of period     1,000,000               1,000,000             As of March 31, 2024 Schedule of options outstanding by exercisable price range                                   Options Outstanding     Options Exercisable   Range of Exercise Price     Number Outstanding   Remaining Average Contractual Life (In Years)     Weighted Average Exercise Price     Number Exercisable   Weighted Average Exercise Price   $ 0.225     100,000     4.21     $ 0.225     100,000   $ 0.225   As of December 31, 2023         Options Outstanding     Options Exercisable     Range of Exercise Price     Number Outstanding     Remaining Average Contractual Life (In Years)     Weighted Average Exercise Price     Number Exercisable   Weighted Average Exercise Price   $ 0.225     100,000     4.46   $ 0.225     100,000 $ 0.225

v3.24.1.1.u2

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events   On April 14, 2024, the company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date after one year of execution, or a date in the which the company secures one million in total investment capital, whichever occurs first.

v3.24.1.1.u2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Use of Accounting Estimates	Use of Accounting Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgment is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash   Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable   Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $58 and $58 as of March 31, 2024 and December 31, 2023, respectively.
Revenue Recognition	Revenue Recognition   The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) and Accounting Standard Codification (ASC) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition.   We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue.   Our percentages of revenue by type for the three months ended March 31, 2024 and 2023 are as follows: Schedule of percentage of revenue                 Three months ended       March 31,       (Unaudited)       2024     2023   Internet content subscriptions     0.0 %     0.0 % Nutritional supplements     0.0 %     0.0 %
Shipping and Handling Costs	Shipping and Handling Costs   We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Loss Per Share	Loss Per Share   Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 100,000 and 585,766 shares for the three months ended March 31, 2024 and 2023, respectively.
Income Taxes	Income Taxes   The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases.   Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.   We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation   We account for stock based instruments issued to employees and non-employees for services in accordance with ASC Topic 718.   Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value.   The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value:     · the stock option exercise price;   · the expected term of the option;   · the grant date price of our common stock, which is issuable upon exercise of the option;   · the expected volatility of our common stock;   · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and   · the risk-free interest rate for the expected option term.   Expected Dividends. We have never declared or paid any cash dividends on any of our capital stock and do not expect to do so in the foreseeable future. Accordingly, we use an expected dividend yield of zero to calculate the grant-date fair value of a stock option.   Expected Volatility. The expected volatility is a measure of the amount by which our stock price is expected to fluctuate during the expected term of options granted. We determine the expected volatility solely based upon the historical volatility of our common stock over a period commensurate with the option’s expected term. We do not believe that the future volatility of our common stock over an option’s expected term is likely to differ significantly from the past.   Risk-Free Interest Rate. The risk-free interest rate is the implied yield available on U.S. Treasury zero-coupon issues with a remaining term equal to the option’s expected term on the grant date.   Expected Term. For option grants subsequent to the adoption of the fair value recognition provisions of the accounting standards, the expected life of stock options granted is based on the actual vesting date and the end of the contractual term.   Grant Date Price of Common Stock. The closing market price of our common stock on the date of grant.
Fair Value of Financial Instruments	Fair Value of Financial Instruments   We follow ASC 820-10, “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.   The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:   Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price.   Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments.   Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity.   The carrying amounts of our cash, holdback receivable, prepaid expenses and other current assets, and accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of March 31, 2024 and December 31, 2023.
Recent Accounting Pronouncements	Recent Accounting Pronouncements   We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

v3.24.1.1.u2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of percentage of revenue	Schedule of percentage of revenue                 Three months ended       March 31,       (Unaudited)       2024     2023   Internet content subscriptions     0.0 %     0.0 % Nutritional supplements     0.0 %     0.0 %

v3.24.1.1.u2

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of notes payable	Schedule of notes payable                   Type   Original Amount Origination Date Maturity Date Annual Interest Rate   Balance at March 31, 2024   Balance at December 31, 2023 Note Payable** (a) $ 50,000 11/18/2019 5/22/2020 5% $ 50,000 $ 50,000 Note Payable** (b) $ 25,000 11/18/2019 5/22/2020 5% $ 25,000 $ 25,000 Note Payable** (c) $ 27,000 05/20/2020 4/20/2022 1% $ $8,307 $ 8,307 Note Payable** (d) $ 10,000 10/27/2020 5/1/2021 5% $ 10,000 $ 10,000 Note Payable** (e) $ 19,500 12/17/2020 6/21/2021 5% $ 19,500 $ 19,500 Note Payable** (f) $ 10,000 4/15/2021 10/18/2021 5% $ 10,000 $ 10,000 Note Payable** (g) $ 20,000 5/10/2021 11/12/2021 5% $ 20,000 $ 20,000 Note Payable** (h) $ 15,000 8/4/2021 2/6/2022 5% $ 15,000 $ 15,000 Note Payable** (i) $ 50,000 9/28/2021 4/2/2022 5% $ 50,000 $ 50,000 Note Payable** (j) $ 15,000 12/1/2021 6/5/2022 5% $ 15,000 $ 15,000 Note Payable** (k) $ 20,000 1/26/2022 7/31/2022 5% $ 20,000 $ 20,000 Note Payable** (l) $ 20,000 2/10/2022 8/15/2022 5% $ 20,000 $ 20,000 Note Payable** (m) $ 40,000 5/18/2022 11/20/2022 5% $ 40,000 $ 40,000 Note Payable** (n) $ 20,000 8/12/2022 2/14/2023 5% $ 20,000 $ 20,000 Note Payable** (o) $ 25,000 10/20/2022 4/24/2023 5% $ 25,000 $ 25,000 Note Payable** (p) $ 20,000 1/12/2023 7/17/2023 5% $ 20,000 $ 20,000 Note Payable** (q) $ 60,000 3/1/2023 9/3/2023 5% $ 60,000 $ 60,000 Note Payable** (r) $ 10,000 5/17/2023 11/19/2023 5% $ 10,000 $ 10,000 Note Payable (s) $ 20,000 10/25/2023 4/28/2024 5% $ 20,000 $ 20,000 Note Payable (t) $ 15,000 11/22/2023 5/26/2024 5% $ 15,000 $ 15,000 Note Payable (u) $ 15,000 12/27/2023 6/30/2024 5% $ 15,000 $ 15,000 Note Payable (v) $ 20,000 2/14/2024 6/30/2024 5% $ 20,000 $ —                               Balance $ 507,807 $ 487,807           Less current portion $ (507,807) $ (487,807)           Total long-term $ — $ — ** Currently in default (a) On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020 $1,250 of accrued interest was paid.   (b) On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (c) On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. We have used the entire loan amount for qualifying expenses and the forgiveness is pending the completion of the application. The Company received a $6,250 courtesy credit from the lender on September 15, 2021. As of March 31, 2024 and December 31, 2023 , the loan balance was $7,808 and 8,833, respectively. The monthly payment beginning October 4, 2021 is $3,433. The Company has submitted the application for forgiveness of the PPP Loan in accordance with the terms of the CARES Act and are in discussions with Bank of America (the lender). During the loan forgiveness process, repayment is temporarily deferred for borrowers until the SBA remits the final loan forgiveness amount to the lender. If granted full forgiveness, Bank of America confirmed that interest and penalties would be removed along with the principal of the loan.   (d) On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (e) On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (f) On April 15, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (g) On May 10, 2021, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (h) On August 4, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (i) On September 28, 2021, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (j) On December 1, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (k) On January 26, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (l) On February 10, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. (m) On May 18, 2022, the Company executed a note payable to an individual in the amount of $40,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (n) On August 12, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. (o) On October 20, 2022, the Company executed a note payable to an individual in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first   (p) On January 12, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (q) On March 2, 2023, the Company executed a note payable to an individual in the amount of $60,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (r) On May 19, 2023, the Company executed a note payable to an individual in the amount of $10,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. (s) On October 25, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (t) On November 22, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (u) On December 27, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.   (v) On February 14, 2024, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.
Schedule of related parties notes payable	Schedule of related parties notes payable                   Type   Original Amount Origination Date Maturity Date Annual Interest Rate   Balance at March 31, 2024   Balance at December 31, 2023 Note Payable (RP)** (w) $ 15,000 3/16/2021 9/18/2021 5% $ 15,000 $ 15,000 Note Payable (RP)** (x) $ 25,000 6/23/2023 12/26/2023 5% $ 25,000 $ —                               Balance $ 40,000 $ 15,000           Less current portion $ (40,000) $ (15,000)           Total long-term $ — $ — ** Currently in default (w) On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.   (x) On July 5, 2022, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

v3.24.1.1.u2

Stockholders’ Deficit (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of warrants outstanding and exercisable	Schedule of warrants outstanding and exercisable                                     2024     2023       Warrants     Weighted Average Exercise Price     Warrants     Weighted Average Exercise Price   Outstanding, beginning of year     —       $ —         485,766     $ 0.364   Granted     —         —         —         —     Exercised     —         —         —         —     Forfeited     —         —         —         —     Expired     —         —         485,766       —     Outstanding, end of year     —       $ —         —       $ —     Exercisable, end of year     —       $ —         —       $ —

v3.24.1.1.u2

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of information about stock options outstanding and exercisable	Schedule of information about stock options outstanding and exercisable                             March 31, 2024 (Unaudited)     December 31, 2023                                           Weighted               Weighted                 Average               Average                 Exercise               Exercise         Options       Price       Options       Price   Outstanding, beginning of period     100,000     $ 0.225       100,000     $ 0.225        Granted     —         —         —         —          Exercised     —         —         —         —          Forfeited     —         —         —         —          Expired     —         —         —         —     Outstanding, end of period     100,000     $ 0.225       100,000     $ 0.225   Exercisable, end of period     100,000     $ 0.225       100,000     $ 0.225                                     Options available for future grant, end of period     1,000,000               1,000,000
Schedule of options outstanding by exercisable price range	Schedule of options outstanding by exercisable price range                                   Options Outstanding     Options Exercisable   Range of Exercise Price     Number Outstanding   Remaining Average Contractual Life (In Years)     Weighted Average Exercise Price     Number Exercisable   Weighted Average Exercise Price   $ 0.225     100,000     4.21     $ 0.225     100,000   $ 0.225   As of December 31, 2023         Options Outstanding     Options Exercisable     Range of Exercise Price     Number Outstanding     Remaining Average Contractual Life (In Years)     Weighted Average Exercise Price     Number Exercisable   Weighted Average Exercise Price   $ 0.225     100,000     4.46   $ 0.225     100,000 $ 0.225

v3.24.1.1.u2

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ 80,616	$ 74,567
Working capital	817,042
Accumulated deficit	2,604,954		$ 2,524,338
Net of reserve for refunds	$ 12,430		$ 13,411

v3.24.1.1.u2

Summary of Significant Accounting Policies (Percentage of Revenue by Type) (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Internet Content Subscriptions [Member]
Product Information [Line Items]
Concentration risk, percentage	0.00%	0.00%
Nutritional Supplements [Member]
Product Information [Line Items]
Concentration risk, percentage	0.00%	0.00%

v3.24.1.1.u2

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accounting Policies [Abstract]
Net of a reserve for refunds	$ 58		$ 58
Potentially dilutive shares	100,000	585,766

v3.24.1.1.u2

Related Party Transactions (Details Narrative) - USD ($)					3 Months Ended		12 Months Ended
	Jan. 23, 2024	Jul. 05, 2023	Mar. 16, 2021	Jun. 14, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Options issued					0		0
Exercise price					$ 0		$ 0
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Expected term				10 years
Options issued				100,000
Exercise price				$ 0.225
In-kind contribution of service					$ 32,500	$ 32,500
Mr Sergei Stetsenko [Member] | Christos Livadas [Member]
Related Party Transaction [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	1,250,000
Note Payable [Member] | Mr Sergei Stetsenko [Member]
Related Party Transaction [Line Items]
Note payable		$ 25,000
Interest rate		5.00%
Secured term description		due date after one year of execution, or a date in the which the company secures one million in total investment capital, whichever occurs first.
Accrued interest					969		$ 657
Note Payable 1 [Member] | Mr Sergei Stetsenko [Member]
Related Party Transaction [Line Items]
Note payable			$ 15,000
Interest rate			5.00%
Secured term description			due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest					$ 2,285		$ 2,098

v3.24.1.1.u2

Notes Payable (Details) - USD ($)		3 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Notes payable		$ 507,807	$ 487,807
Less current portion		(507,807)	(487,807)
Total long-term		0	0
Note Payable A [Member]
Short-Term Debt [Line Items]
Original Amount	[1]	$ 50,000
Origination Date	[1]	Nov. 18, 2019
Maturity Date	[1]	May 22, 2020
Interest rate	[1]	5.00%
Note payable	[1]	$ 50,000	50,000
Note Payable B [Member]
Short-Term Debt [Line Items]
Original Amount	[2]	$ 25,000
Origination Date	[2]	Nov. 18, 2019
Maturity Date	[2]	May 22, 2020
Interest rate	[2]	5.00%
Note payable	[2]	$ 25,000	25,000
Note Payable C [Member]
Short-Term Debt [Line Items]
Original Amount	[3]	$ 27,000
Origination Date	[3]	May 20, 2020
Maturity Date	[3]	Apr. 20, 2022
Interest rate	[3]	1.00%
Note payable	[3]	$ 8,307	8,307
Note Payable D [Member]
Short-Term Debt [Line Items]
Original Amount	[4]	$ 10,000
Origination Date	[4]	Oct. 27, 2020
Maturity Date	[4]	May 01, 2021
Interest rate	[4]	5.00%
Note payable	[4]	$ 10,000	10,000
Note Payable E [Member]
Short-Term Debt [Line Items]
Original Amount	[5]	$ 19,500
Origination Date	[5]	Dec. 17, 2020
Maturity Date	[5]	Jun. 21, 2021
Interest rate	[5]	5.00%
Note payable	[5]	$ 19,500	19,500
Note Payable F [Member]
Short-Term Debt [Line Items]
Original Amount	[6]	$ 10,000
Origination Date	[6]	Apr. 15, 2021
Maturity Date	[6]	Oct. 18, 2021
Interest rate	[6]	5.00%
Note payable	[6]	$ 10,000	10,000
Note Payable G [Member]
Short-Term Debt [Line Items]
Original Amount	[7]	$ 20,000
Origination Date	[7]	May 10, 2021
Maturity Date	[7]	Nov. 12, 2021
Interest rate	[7]	5.00%
Note payable	[7]	$ 20,000	20,000
Note Payable H [Member]
Short-Term Debt [Line Items]
Original Amount	[8]	$ 15,000
Origination Date	[8]	Aug. 04, 2021
Maturity Date	[8]	Feb. 06, 2022
Interest rate	[8]	5.00%
Note payable	[8]	$ 15,000	15,000
Note Payable I [Member]
Short-Term Debt [Line Items]
Original Amount	[9]	$ 50,000
Origination Date	[9]	Sep. 28, 2021
Maturity Date	[9]	Apr. 02, 2022
Interest rate	[9]	5.00%
Note payable	[9]	$ 50,000	50,000
Note Payable J [Member]
Short-Term Debt [Line Items]
Original Amount	[10]	$ 15,000
Origination Date	[10]	Dec. 01, 2021
Maturity Date	[10]	Jun. 05, 2022
Interest rate	[10]	5.00%
Note payable	[10]	$ 15,000	15,000
Note Payable K [Member]
Short-Term Debt [Line Items]
Original Amount	[11]	$ 20,000
Origination Date	[11]	Jan. 26, 2022
Maturity Date	[11]	Jul. 31, 2022
Interest rate	[11]	5.00%
Note payable	[11]	$ 20,000	20,000
Note Payable L [Member]
Short-Term Debt [Line Items]
Original Amount	[12]	$ 20,000
Origination Date	[12]	Feb. 10, 2022
Maturity Date	[12]	Aug. 15, 2022
Interest rate	[12]	5.00%
Note payable	[12]	$ 20,000	20,000
Note Payable M [Member]
Short-Term Debt [Line Items]
Original Amount	[13]	$ 40,000
Origination Date	[13]	May 18, 2022
Maturity Date	[13]	Nov. 20, 2022
Interest rate	[13]	5.00%
Note payable	[13]	$ 40,000	40,000
Note Payable N [Member]
Short-Term Debt [Line Items]
Original Amount	[14]	$ 20,000
Origination Date	[14]	Aug. 12, 2022
Maturity Date	[14]	Feb. 14, 2023
Interest rate	[14]	5.00%
Note payable	[14]	$ 20,000	20,000
Note Payable O [Member]
Short-Term Debt [Line Items]
Original Amount	[15]	$ 25,000
Origination Date	[15]	Oct. 20, 2022
Maturity Date	[15]	Apr. 24, 2023
Interest rate	[15]	5.00%
Note payable	[15]	$ 25,000	25,000
Note Payable P [Member]
Short-Term Debt [Line Items]
Original Amount	[16]	$ 20,000
Origination Date	[16]	Jan. 12, 2023
Maturity Date	[16]	Jul. 17, 2023
Interest rate	[16]	5.00%
Note payable	[16]	$ 20,000	20,000
Note Payable Q [Member]
Short-Term Debt [Line Items]
Original Amount	[17]	$ 60,000
Origination Date	[17]	Mar. 01, 2023
Maturity Date	[17]	Sep. 03, 2023
Interest rate	[17]	5.00%
Note payable	[17]	$ 60,000	60,000
Note Payable R [Member]
Short-Term Debt [Line Items]
Original Amount	[18]	$ 10,000
Origination Date	[18]	May 17, 2023
Maturity Date	[18]	Nov. 19, 2023
Interest rate	[18]	5.00%
Note payable	[18]	$ 10,000	10,000
Note Payable S [Member]
Short-Term Debt [Line Items]
Original Amount	[19]	$ 20,000
Origination Date	[19]	Oct. 25, 2023
Maturity Date	[19]	Apr. 28, 2024
Interest rate	[19]	5.00%
Note payable	[19]	$ 20,000	20,000
Note Payable T [Member]
Short-Term Debt [Line Items]
Original Amount	[20]	$ 15,000
Origination Date	[20]	Nov. 22, 2023
Maturity Date	[20]	May 26, 2024
Interest rate	[20]	5.00%
Note payable	[20]	$ 15,000	15,000
Note Payable U [Member]
Short-Term Debt [Line Items]
Original Amount	[21]	$ 15,000
Origination Date	[21]	Dec. 27, 2023
Maturity Date	[21]	Jun. 30, 2024
Interest rate	[21]	5.00%
Note payable	[21]	$ 15,000	15,000
Note Payable V [Member]
Short-Term Debt [Line Items]
Original Amount	[22]	$ 20,000
Origination Date	[22]	Feb. 14, 2024
Maturity Date	[22]	Jun. 30, 2024
Interest rate	[22]	5.00%
Note payable	[22]	$ 20,000	$ 0
[1] On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020 $1,250 of accrued interest was paid. [2] On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [3] On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. We have used the entire loan amount for qualifying expenses and the forgiveness is pending the completion of the application. The Company received a $6,250 courtesy credit from the lender on September 15, 2021. As of March 31, 2024 and December 31, 2023 , the loan balance was $7,808 and 8,833, respectively. The monthly payment beginning October 4, 2021 is $3,433. The Company has submitted the application for forgiveness of the PPP Loan in accordance with the terms of the CARES Act and are in discussions with Bank of America (the lender). During the loan forgiveness process, repayment is temporarily deferred for borrowers until the SBA remits the final loan forgiveness amount to the lender. If granted full forgiveness, Bank of America confirmed that interest and penalties would be removed along with the principal of the loan. [4] On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [5] On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [6] On April 15, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [7] On May 10, 2021, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [8] On August 4, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [9] On September 28, 2021, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [10] On December 1, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [11] On January 26, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [12] On February 10, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [13] On May 18, 2022, the Company executed a note payable to an individual in the amount of $40,000, interest accrues at 5% per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [14] On August 12, 2022, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [15] On October 20, 2022, the Company executed a note payable to an individual in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first [16] On January 12, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [17] On March 2, 2023, the Company executed a note payable to an individual in the amount of $60,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [18] On May 19, 2023, the Company executed a note payable to an individual in the amount of $10,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [19] On October 25, 2023, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [20] On November 22, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [21] On December 27, 2023, the Company executed a note payable to an individual in the amount of $15,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first. [22] On February 14, 2024, the Company executed a note payable to an individual in the amount of $20,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

v3.24.1.1.u2

Notes Payable (Details 1) - USD ($)		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Notes payable related parties		$ 40,000	$ 15,000
Less current portion		(40,000)	(15,000)
Long term debt		0	0
Note Payable W [Member]
Short-Term Debt [Line Items]
Original Amount	[1]	$ 15,000
Origination Date	[1]	Mar. 16, 2021
Maturity Date	[1]	Sep. 18, 2021
Interest rate	[1]	5.00%
Note payable	[1]	$ 15,000	15,000
Note Payable X [Member]
Short-Term Debt [Line Items]
Original Amount	[2]	$ 25,000
Origination Date	[2]	Jun. 23, 2023
Maturity Date	[2]	Dec. 26, 2023
Interest rate	[2]	5.00%
Note payable	[2]	$ 25,000	$ 0
[1] On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. [2] On July 5, 2022, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $25,000, interest accrues 5% per annum, unsecured, and due date one year after execution, or the date in the which the company seems one million in total investment capital, whichever occurs first.

v3.24.1.1.u2

Notes Payable (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2022
Debt Disclosure [Abstract]
Non related party notes payable	$ 56,442	$ 50,364

v3.24.1.1.u2

Commitments and Contingencies (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Jun. 14, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options issued		0		0
Exercise price		$ 0		$ 0
In-kind contribution of service		$ 32,500	$ 32,500
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Annual base salary	$ 130,000
Expected life	10 years
Options issued	100,000
Exercise price	$ 0.225

v3.24.1.1.u2

Stockholders' Equity (Information About Warrants Outstanding and Exercisable) (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, beginning of period	0	485,766
Weighted average exercise price outstanding, beginning of period	$ 0	$ 0.364
Warrants, Granted	0	0
Weighted average exercise price, Granted	$ 0	$ 0
Warrants, Exercised	0	0
Weighted average exercise price, Exercised	$ 0	$ 0
Warrants, Forfeited	0	0
Weighted average exercise price, Forfeited	$ 0	$ 0
Warrants, Expired	0	485,766
Weighted average exercise price, Expired	$ 0	$ 0
Warrants outstanding, end of period	0	0
Weighted average exercise price outstanding, end of period	$ 0	$ 0
Warrants, Exercisable, end of year	0	0
Weighted average exercise price exercisable, end of year	$ 0	$ 0

v3.24.1.1.u2

Stockholders’ Deficit (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized				50,000,000		50,000,000
Common stock, par value				$ 0.0001		$ 0.0001
Preferred stock, shares authorized				5,000,000		5,000,000
Preferred stock, par value				$ 0.0001		$ 0.0001
Common stock, shares outstanding				11,599,830		11,599,830
In-kind contribution of service				$ 32,500	$ 32,500
Intrinsic value				$ 0		$ 0
C R G Finance A G [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued		368,111	17,655
Exercise price		$ 0.225	$ 0.225
Fair value of warrants		$ 34,405	$ 1,670
Offering price		$ 0.225	$ 0.225
Expected volatility rate		45.00%	45.00%
Risk free interest rate		2.20%	2.51%
Expected life		5 years	5 years
Scientific Advisor [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants issued	100,000
Exercise price	$ 0.90
Fair value of warrants	$ 1,905
Offering price	$ 0.225
Expected volatility rate	45.00%
Risk free interest rate	2.63%
Expected life	5 years
Warrants vested				0		0

v3.24.1.1.u2

Stock Option Plan (Stock Options Outstanding) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Options outstanding, beginning of period	100,000	100,000
Weighted average exercise price outstanding, beginning of period	$ 0.225	$ 0.225
Options, Granted	0	0
Weighted average exercise price, Granted	$ 0	$ 0
Options, Exercised	0	0
Weighted average exercise price, Exercised	$ 0	$ 0
Options, Forfeited	0	0
Weighted average exercise price, Forfeited	$ 0	$ 0
Options, Expired	0	0
Weighted average exercise price, Expired	$ 0	$ 0
Options outstanding, end of period	100,000	100,000
Weighted average exercise price outstanding, end of period	$ 0.225	$ 0.225
Options outstanding Exercisable, end of period	100,000	100,000
Weighted average exercise price, Exercisable end of period	$ 0.225	$ 0.225
Options available for grant	1,000,000	1,000,000

v3.24.1.1.u2

Stock Option Plan (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Upper	$ 0.225	$ 0.225
Number Outstanding	100,000	100,000
Remaining Average Contractual Life	4 years 2 months 15 days	4 years 5 months 15 days
Weighted Average Exercise Price	$ 0.225	$ 0.225
Number Exercisable	100,000	100,000
Exercisable Weighted Average Exercise Price	$ 0.225	$ 0.225

v3.24.1.1.u2

Stock Option Plan (Details Narrative) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 14, 2018	Mar. 31, 2024	Dec. 31, 2023
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Total awards reserved		1,100,000
Options issued		0	0
Exercise price		$ 0	$ 0
Intrinsic value		$ 0	$ 0
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45.00%
Risk free rate	2.20%
Expected term	10 years

v3.24.1.1.u2

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Apr. 14, 2024 USD ($)
Subsequent Event [Line Items]
Note payable	$ 15,000
Interest rate	5.00%

---